Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — Total other income, net

Similar metrics at other companies

Vaxcyte, Inc. logo
PCVXReportable Segment — Total other income, net
$25.23M-37.0%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Total other income, net
$12.53M-14.3%
LiveRamp Holdings, Inc. logo
RAMPReportable Segment — Total other income, net
$3.09M-16.7%
Enphase Energy logo
ENPHReportable Segment — Total other income, net
$10.38M+99.7%
Prime Medicine logo
PRMEReportable Segment — Total other income, net
$1.18M+49.6%
Bicara Therapeutics logo
BCAXReportable Segment — Total other income
$4.08M-18.6%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other research and development4,8414,432
Total research and development57,09446,889
Selling, general and administrative80,25460,413
Royalty expense24,81612,425
Total other income, net1931,487
Income tax benefit (provision)120(39)
Loss from discontinued operations, net of tax(500)
Net loss$(37,102)$(41,226)

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — total other income, net?
Travere Therapeutics, Inc. (TVTX) reported business segments — total other income, net of $193K in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — total other income, net changed year-over-year?
Travere Therapeutics, Inc.'s business segments — total other income, net decreased by 87.0% year-over-year, from $1.49M to $193K.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — total other income, net?
Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — total other income, net has grown at a 6.1% compound annual growth rate (CAGR), from -$11.34M to $13.55M.
What does business segments — total other income, net mean?
This metric captures non-operating income or expenses, such as interest income, foreign exchange gains or losses, and other miscellaneous financial items. It provides a view of the company's financial performance outside of its core pharmaceutical operations.

Ask your AI about Travere Therapeutics, Inc.'s business segments — total other income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude